RxDoctor Payments DataLook up a doctor →

John Trotter, MD

Interventional Cardiology · Mobile, ALNPI 1558405902

Payments from drug & device makers

$122,069in general payments, 2019–2025

Across 624 payments — averaging $195.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$113K
  • Abbott$8K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$95
  • Medtronic$89
  • Amgen$45
  • Abiomed$27
  • plus $101 from 5 others

What the payments were for

  • Food & beverage$398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$122,069 in reported general payments places this provider in the 85th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$652,233
Medicare patients
1,706
Services billed
8,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban548$552,919
Repatha SureclickEvolocumab143$112,098
EntrestoSacubitril/Valsartan83$107,986
XareltoRivaroxaban102$106,471
FarxigaDapagliflozin Propanediol36$29,026
MultaqDronedarone Hcl17$28,766
Repatha SyringeEvolocumab17$14,697
Atorvastatin Calcium860$10,294
JardianceEmpagliflozin12$10,199
BrilintaTicagrelor11$9,206
Ranolazine ErRanolazine62$7,847
Metoprolol Succinate484$6,730
Rosuvastatin Calcium464$6,711
Praluent PenAlirocumab12$6,699
Isosorbide Dinitrate75$4,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$15$10,19912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →